Results 31 to 40 of about 605,792 (294)

Treatment options for PNET liver metastases. a systematic review [PDF]

, 2018
Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo, Crovetto, Anna, Debs, Tarek, Mangogna, Livia Maria, Moschetta, Giovanni, Nigri, Giuseppe, Persechino, Raffaello, Petrucciani, Niccolò, Ramacciato, Giovanni   +8 more
core   +1 more source

Human Pancreas GH-Releasing Factor Analog Restores High-Amplitude GH Pulses in CNS Lesion-Induced GH Deficiency [PDF]

, 1983
Lesions of the ventromedial-arcuate (VMH-ARC) region of the hypothalamus result in impaired growth accompanied by a marked suppression in spontaneous GH secretory bursts. We studied the effects of an analog of the recently characterized human pancreas GH-
Eikelboom, Rudy, Ling, Nicholas, Schaffer Tannenbaum, Gloria   +2 more
core   +2 more sources

Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma

Frontiers in Oncology, 2020
Somatostatin receptor (SSTR) 2, widely expressed in meningioma, is a G-protein-coupled receptor and can be activated by somatostatin or its synthetic analogs.
Wei Wu, Yunxiang Zhou, Yali Wang, Lihong Liu, Jianyao Lou, Yongchuan Deng, Peng Zhao, Anwen Shao   +7 more
doaj   +1 more source

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group [PDF]

, 2019
Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established.
Badalamenti, G., Bianco, A., Colao, A., De Divitiis, C., Di Maio, S., Di Sarno, A., Dolce, P., Faggiano, A., Guarnotta, V., Leo, S., Mocerino, C., Modica, R., Ottaviano, M., Palmieri, G., Puliafito, I., Riccardi, F., Tafuto, S., Tozzi, L.   +17 more
core   +1 more source

A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide

Clinical Case Reports, 2021
Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR.
Keiko Yamaoka, Shuichi Nagashima, Nobukazu Okada, Nagisa Sawayama, Shinsuke Saito, Manabu Takahashi, Kenta Okada, Kazuhiro Endo, Masaru Koizumi, Hideki Sasanuma, Ken Ebihara, Atsuko Kasajima, Noriyoshi Fukushima, Naohiro Sata, Shun Ishibashi   +14 more
doaj   +1 more source

E-cadherin expression is associated with somatostatin analogue response in acromegaly [PDF]

, 2018
Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin‐like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity. Somatostatin analogues (SSAs)
Cano, David A., Castaño, Justo P., Dios, Elena, Flores Martínez, Álvaro, Ibáñez Costa, Alejandro, Japón Rodríguez, Miguel Ángel, Luque, Raúl M., Madrazo Atutxa, Ainara, Soto Moreno, Alfonso Manuel, Venegas Moreno, Eva, Vázquez Borrego, Mari C.   +10 more
core   +1 more source

Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging

Diagnostics, 2023
Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) is a heterogeneous and complex group of tumors that are often difficult to classify due to their heterogeneity and varying locations.
Daniel Vogele, Stefan A. Schmidt, Daniel Gnutzmann, Wolfgang M. Thaiss, Thomas J. Ettrich, Marko Kornmann, Meinrad Beer, Markus S. Juchems   +7 more
doaj   +1 more source

Resistance to Somatostatin Analogs in Acromegaly [PDF]

Endocrine Reviews, 2010
Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant treatment after surgery. First-line treatment with these drugs is generally used in the patients with macroadenomas or in those with clinical conditions so severe as to prevent unsafe reactions during anesthesia.
Colao, Annamaria, Auriemma, Renata S., Lombardi, Gaetano, Pivonello, Rosario   +3 more
openaire   +4 more sources

Pasireotide for the Medical Management of Feline Hypersomatotropism [PDF]

, 2015
BACKGROUND: Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST.
Abraham, Adams, Alt, Appleton, Bhayana, Bruns, Castillo, Church, Colao, Colao, Cuevas-Ramos, Fedele, Fernandez-Rodriguez, Fougner, Golor, Henry, Hofland, Juul, Katznelson, Kvols, Lamb, Lamberts, Maxwell, Meij, Miller, Murray, Myers, Niessen, Niessen, Niessen, Niessen, Petrus, Polska, Rand, Ray, Schmid, Schmid, Sheppard, Slingerland, Sohmiya, Starkey, Stolk, Taboada, Wajchenberg, Zatelli, Zou   +45 more
core   +2 more sources

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. [PDF]

, 2013
BACKGROUND: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are heterogeneous with respect to biological behaviour and prognosis. As angiogenesis is a renowned pathogenic hallmark as well as a therapeutic target, we aimed to investigate the ...
A Couvelard, A Giatromanolaki, A Rinke, AM Marion-Audibert, AT Dimou, B Terris, D Hanahan, D J Pinato, D O’Toole, DC Metz, DJ Pinato, DJ Pinato, E Raymond, EP Hui, F Panzuto, G Kloppel, HS Kim, I Albrecht, IM Modlin, J LeCouter, J Strosberg, J Zhang, JC Yao, JT Chi, JY Scoazec, K Hirabayashi, K Meeran, K Villaume, M Dal Monte, M Perigny, M Ruscica, MA Maynard, N Martin, N Ngo, P Kuiper, R Dina, R Katoh, R Mentlein, R Ramachandran, R Sharma, S Ezziddin, S T K Toussi, T M Tan, VD Corleto, Y Arvidsson, Y Seo, Y Takahashi, YC Patel   +47 more
core   +6 more sources